补肾法治疗慢性再生障碍性贫血的临床研究

目的:观察补肾法治疗慢性再生障碍性贫血的临床疗效。方法:收集2007年1月—2012年1月在浙江中医药大学附属第一医院的门诊及住院69例病人。将患者进行辨证分型,其中肾阳虚组(23例)、肾阴虚组(19例)、肾阴阳两虚组(27例),然后进行奇偶数字随机抽取,分为中医治疗组和西医治疗组,其中中医治疗组36例中肾阳虚组(12例)、肾阴虚组(10例)、肾阴阳两虚组(14例);西医组33例中肾阳虚组(11例)、肾阴虚组(9例)、肾阴阳两虚组(13例)。以3个月为1个疗程,通过2个疗程的治疗后观察患者中医证候、外周血象及骨髓象变化。结果:①中医组治疗慢性再障在改善中医证候方面与西医组比较,具有显著性差异(P<0.05)。②中医组治疗前后相比血红蛋白、白细胞计数、血小板计数、网织红细胞均有不同程度的升高,肾阳虚型中医组与西医组治疗后相比,外周血细胞增长优于西医组,两者有差异(P<0.05)。③中医组治疗慢性再障过程中的不良反应较西医组轻。结论:补肾法治疗慢性再生障碍性贫血能明显改善临床症状,提高临床疗效,降低药物不良反应,为中西医结合治疗慢性再障提供较好的治疗方案。

Clinical Study of Bushen Therapy Treating Chronic Aplastic Anemia

Objective：The clinical efficacy of Bushen therapy of chronic aplastic anemia was observed. Method：69 pa- tients in outpatient and inpatient of The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine were collected during January 2007 -January 2012. Patients were divided into kidney Yang deficiency group （23 cases）, kidney Yin deficiency group （19 cases） , kidney Yang- Yin deficiency group （27 cases） , and randomly selected and di- vided into traditional Chinese medicine treatment groups and Western medicine treatment groups, including Chinese medi- cine treatment group of 36 patients in which the kidney Yang deficiency group （12 cases） , kidney Yin deficiency group （10 case） ,kidney Yang -Yin deficiency group （14 cases） ;the WM group of 33 cases in which kidney Yang deficiency group （11 cases） ,kidney Yin deficiency group （9 cases）,kidney Yang- Yin deficiency group （13 cases） . For a course of three months , through the observation of patients after two courses of treatment, TCM climate changes in the pe- ripheral blood and bone marrow were observed. Results ： （1）Chinese medicine group treatment of chronic aplastic anemia in improving TCM syndrome compared with Western medicine group had a significant difference （ P 〈 0. 05 ）. （2）TCM group＇ s hemoglobin, white blood cell count, platelet count and reticulocytes before and after treatment had different levels of elevation, kidney Yang deficiency group of TCM group＇ s peripheral blood cell growth was better than that of Western medicine group after treatment with significant difference （ P 〈 0.05 ）. （3）TCM group treatment had lighter side effects than Western group. Conclusion ： Bushen therapy can significantly improve the clinical symptoms of chronic aplastic anemia, improve clinical outcomes and reduce drug side effects, providing better treatment options for integrative treatment of chronic aplastic anemia.